Heart Failure With Preserved Ejection Fraction: Evaluation and Recognition by CMR
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of East Anglia
About this trial
Heart failure with preserved ejection fraction (HFpEF) is a common and growing condition with a poor prognosis but the pathophysiology and management are still being investigated. The PREFER-CMR project aims to evaluate and validate the application of novel 4D cardiac magnetic resonance flow dynamic methods to measure left ventricular pressures and validate these measurements with direct pressure measurement by coronary angiography. This is a prospective observational study of patients with HFpEF undergoing clinical evaluation with coronary angiography who will also undergo contemporaneous cardiac MRI. The primary outcome will be the level of agreement between the two methods using angiography as the reference method.
Eligibility criteria
Qualifiers
Adults: age≥18 years.
Typical HF symptoms (NYHA stage>I) within the last six months.
Raised NTproBNP (>400 pg/ml)
EF>50 % with the absence of structural heart disease on TTE (except left ventricular hypertrophy or left atrial enlargement).
Disqualifiers
Patients unable/unwilling to provide informed consent.
Bodyweight>120 kg or inability to lie flat/still.
Contraindication for invasive workup (allergy to contrast, severe renal insufficiency with estimated glomerular filtration rate (eGRF)<30 ml/min).
Contraindications for a contrast-enhanced CMR study (allergy to contrast, incompatible devices or implants, severe claustrophobia).
Trial design
Treatments tested in this trial
- Multi Parametric Cardiac Magnetic Resonance
Treatment groups
100 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
University of East Anglia
Lead sponsor
Clinical Research and Trials Unit (Norfolk & Norwich University Hospital, UK)
Collaborator
Source ClinicalTrials.gov